Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.33 |
| ▸ | KMO | O15229 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.30 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.30 |
| ▸ | GRM5 | P41594 | 2/20 | 0.30 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10163925 | 0.82 | PYGL (0.40) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL1477690 | 0.82 | GRM5 (0.43) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL23851284 | 0.79 | GRM5 (0.36) | KMOGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL19781318 | 0.79 | — | — | |
| SCHEMBL8771367 | 0.79 | CYP1A1 (0.39) | RAPGEF4FFAR1FFAR4HTR2ASLC6A4 | |
| SCHEMBL19748358 | 0.78 | KDM1A (0.33) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL5993333 | 0.78 | ALDH1A1 (0.42) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL19781336 | 0.78 | — | — | |
| SCHEMBL2805739 | 0.76 | ACACB (0.43) | KMOFFAR4 | |
| SCHEMBL4683351 | 0.76 | RAB9A (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12275718-B2 | Small molecule inhibitors of galectin-3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-04-15 | — | — | US | disclosed |
| US-11939349-B2 | Galactoside inhibitor of galectins | GALECTO BIOTECH AB (DK) | 2024-03-26 | — | — | US | disclosed |
| US-20220380401-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2022-12-01 | — | — | US | disclosed |
| US-11447517-B2 | Galactoside inhibitor of galectins | GALECTO BIOTECH AB (DK) | 2022-09-20 | — | — | US | disclosed |
| US-20220017558-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2022-01-20 | — | — | US | disclosed |
| US-20220009913-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL MYERS SQUIBB CO (US) | 2022-01-13 | — | — | US | disclosed |
| EP-3891144-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | Bristol-Myers Squibb Company (US) | 2021-10-13 | — | — | EP | disclosed |
| EP-3883946-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | Galecto Biotech AB (DK) | 2021-09-29 | — | — | EP | disclosed |
| CN-113412267-A | alpha-D-galactoside inhibitors of galectins | 格莱克特生物技术公司 | 2021-09-17 | — | — | CN | disclosed |
| US-20210147408-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL MYERS SQUIBB CO (US) | 2021-05-20 | — | — | US | disclosed |
| WO-2020117883-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-11 | — | — | WO | disclosed |
| WO-2019067702-A9 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-25 | — | — | WO | disclosed |
| WO-2019067702-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-04 | — | — | WO | disclosed |
| CN-109563119-A | α-D- galactoside the inhibitor of galactose agglutinin | 格莱克特生物技术公司 | 2019-04-02 | — | — | CN | disclosed |
| WO-2018011094-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (DK) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147408-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | LGALS3, LGALS1, LGALS3BP | RAPGEF4 3375/4885KMO 3468/4885GABRA1 3263/4885 |
| US-20220017558-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | LGALS1, LGALS3, LGALS2 | RAPGEF4 3278/4885KMO 3296/4885GABRA1 3564/4885 |
| US-20220380401-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | LGALS1, LGALS3, LGALS2 | RAPGEF4 3278/4885KMO 3296/4885GABRA1 3564/4885 |
| US-20220009913-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | LGALS3, LGALS1, LGALS3BP | RAPGEF4 3375/4885KMO 3468/4885GABRA1 3263/4885 |
| US-12275718-B2 | Small molecule inhibitors of galectin-3 | LGALS3, LGALS1, LGALS3BP | RAPGEF4 3375/4885KMO 3468/4885GABRA1 3263/4885 |
| US-11939349-B2 | Galactoside inhibitor of galectins | LGALS1, LGALS3, LGALS2 | RAPGEF4 3638/4885KMO 3027/4885GABRA1 3375/4885 |
| US-11447517-B2 | Galactoside inhibitor of galectins | LGALS1, LGALS3, LGALS2 | RAPGEF4 3638/4885KMO 3027/4885GABRA1 3375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.